Our pipeline is based on our two proprietary platforms of allogeneic stem cells, which are extracted from human adipose tissue from healthy adult donors or myocardial tissue that would typically be discarded during a routine valve replacement operation. It is our intention to exploit the benefits of our allogeneic stem cell platforms by clinically developing fully approved pharmaceutical products which use the cells’ anti-inflammatory properties for the treatment of inflammatory, autoimmune diseases and heart cardiac diseases.